Literature DB >> 220336

Complement-enhanced neutralizing antibody response to varicella-zoster virus.

C Grose, B J Edmond, P A Brunell.   

Abstract

Humoral immunity following infection with varicella-zoster virus (VZV) was evaluated by a complement-enhanced neutralization test. The specificity of the test was examined and its sensitivity compared with that of the assay which measures antibody to VZV-induced membrane antigen (FAMA). Generally, the titer of neurtalizing antibody was two- to fourfold higher than the FAMA titer. The absence of neutralizing activity at a serum dilution of 1:4 indicated susceptibility of the donor to VZV infection and correlated with an absence of FAMA (titer, less than 1:2). A survey of susceptible leukemic children exposed to chicken pox revealed that several recipients of zoster immune globulin had a subclinical infection, as manifested by seroconversion and persistence of neutralizing antibody to VZV. Results of these studies indicate that the complement-enhanced neutralization test is a sensitive and specific assay for determination of humoral immune status with regard to VZV in healthy and immunosuppressed individuals.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 220336     DOI: 10.1093/infdis/139.4.432

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

Review 1.  Varicella Virus Vaccination in the United States.

Authors:  Jana Shaw; Anne A Gershon
Journal:  Viral Immunol       Date:  2017-11-27       Impact factor: 2.257

2.  Mumps virus-specific antibody titers from pre-vaccine era sera: comparison of the plaque reduction neutralization assay and enzyme immunoassays.

Authors:  Jeremy Mauldin; Kathryn Carbone; Henry Hsu; Robert Yolken; Steven Rubin
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

3.  Determination of immunity to varicella using an enzyme-linked-immunosorbent-assay.

Authors:  A A Gershon; H M Frey; S P Steinberg; M D Seeman; D Bidwell; A Voller
Journal:  Arch Virol       Date:  1981       Impact factor: 2.574

4.  Complement requirement for virus neutralization by antibody and reduced serum complement levels associated with experimental equine herpesvirus 1 infection.

Authors:  D B Snyder; A C Myrup; S K Dutta
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

Review 5.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12

6.  Monoclonal antibodies against three major glycoproteins of varicella-zoster virus.

Authors:  C Grose; D P Edwards; W E Friedrichs; K A Weigle; W L McGuire
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

7.  Comparison of fluorescent-antibody, neutralizing-antibody, and complement-enhanced neutralizing-antibody assays for detection of serum antibody to respiratory syncytial virus.

Authors:  T N Kaul; R C Welliver; P L Ogra
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

8.  Varicella-zoster-associated encephalitis: detection of specific antibody in cerebrospinal fluid.

Authors:  A Gershon; S Steinberg; S Greenberg; L Taber
Journal:  J Clin Microbiol       Date:  1980-12       Impact factor: 5.948

9.  Enzyme-linked immunosorbent assay for detection of antibody to varicella-zoster virus.

Authors:  J Shanley; M Myers; B Edmond; R Steele
Journal:  J Clin Microbiol       Date:  1982-02       Impact factor: 5.948

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.